EXTENSIVE-STAGE SMALL-CELL LUNG CANCER

This study tests whether adding the drug bevacizumab to standard chemo-immunotherapy can help people with extensive-stage small cell lung cancer that has spread to the liver. About 39 participants will receive the combination for up to a year. The goal is to see if it delays canc…

This study tests a new drug called ifinatamab deruxtecan (I-DXd) combined with standard immunotherapy (atezolizumab) and sometimes chemotherapy (carboplatin) for people with extensive-stage small cell lung cancer who have not yet been treated. The goal is to see if the combinatio…

This study tests whether a new drug called BNT327, combined with standard chemotherapy, helps people with advanced small-cell lung cancer live longer compared to another approved drug (atezolizumab) plus the same chemo. About 621 adults who have not yet been treated for their can…

This study tests a combination of two drugs, monalizumab and durvalumab, plus chemotherapy for people with small cell lung cancer. The goal is to see if this mix can keep the cancer from growing longer than standard treatment. About 84 adults with either extensive or limited stag…

This early-phase study tests a new drug called ALPS12 in people with extensive-stage small cell lung cancer that has returned after prior treatment. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 122 participants will ta…

This early-phase study tests two drugs, tarlatamab and AB248, together in people with extensive stage small cell lung cancer that has worsened after at least one prior treatment. The main goals are to check safety and find the best dose. About 380 adults will take part.

This study tests a new treatment for people with extensive stage small cell lung cancer who have not had treatment before. Participants first get standard chemo-immunotherapy, then a maintenance therapy with two drugs: durvalumab and ceralasertib. The goal is to see if this combi…

This study tests a new treatment for people with a specific type of advanced small cell lung cancer (SLFN-11 positive). It combines low-dose radiation with standard chemotherapy and two additional drugs (sugemalimab and olaparib) to see if it is safe and effective. About 45 adult…

This study tests whether adding the drug tarlatamab to standard chemotherapy (durvalumab, carboplatin, etoposide) helps people with untreated extensive-stage small-cell lung cancer live longer. About 330 adults will be randomly assigned to receive either the new combo or standard…

This study tests a new treatment for people with extensive-stage small-cell lung cancer, a type of lung cancer that has spread. The treatment combines the drug tislelizumab with chemotherapy and radiation to the chest. The goal is to see if this combination can help control the c…

This study tests a new drug called tarlatamab, given as a shot under the skin, for people with extensive stage small cell lung cancer that has come back after chemotherapy. The main goals are to check safety and how the body handles the drug. About 220 adults will take part to se…

This study tests whether adding chest radiation to maintenance immunotherapy (atezolizumab) can reduce the chance of cancer returning in the chest for people with extensive-stage small cell lung cancer. About 37 adults whose cancer has shrunk after initial chemo-immunotherapy wil…

This study tests whether a new experimental drug (BMS-986489) combined with standard chemotherapy works better than the current standard treatment (atezolizumab plus chemo) for people with extensive-stage small cell lung cancer. About 530 participants will receive either the new …

This study tests whether a combination of two drugs (lurbinectedin and serplulimab) can help keep extensive-stage small cell lung cancer from growing after initial treatment. About 30 adults whose cancer did not get worse after first-line chemo-immunotherapy will receive the comb…

This study is for people newly diagnosed with extensive-stage small cell lung cancer, a type that has spread. Researchers want to see if adding focused radiation to the standard treatment of durvalumab and chemotherapy can help control the cancer longer. About 49 participants wil…

This program offers the drug I-DXd to adults with extensive-stage small cell lung cancer who have already tried at least two prior treatments, including platinum-based chemotherapy. It is for patients who have no other suitable options and cannot join a clinical trial. The goal i…

This study tests if adding trilaciclib before standard chemotherapy can help people with extensive-stage small cell lung cancer live longer. About 302 participants who have already tried other treatments will receive either trilaciclib or a placebo. The goal is to see if trilacic…

This early-stage study tests whether combining valemetostat with atezolizumab is safe for people with extensive-stage small cell lung cancer after initial treatment. Researchers will find the best dose of valemetostat and check for side effects in 24 participants. The goal is to …

This study looks at whether a special blood test (T cell repertoire technology) can predict how well a combination of the drug tislelizumab and standard chemotherapy works for people with advanced small cell lung cancer. Researchers will enroll 40 patients who have not had treatm…